Investment
Features
FeesSafety
Academy
More
Pluang+

Sandisk rated BUY with 20% upside as AI memory demand and yen cost risks are analyzed.

Analyst Insights
16 Aug 2026
Seeking Alpha
View Source
Bullish
pluang ai news

An analyst initiates coverage of Sandisk with a BUY rating, highlighting the company's exposure to yen costs through its joint venture with Kioxia Holdings in Japan. Although Sandisk does not own its manufacturing fabs, its high margins and cash flow targets depend on Flash Ventures, which incurs costs in yen. The market currently underestimates Sandisk's stable earnings outlook for 2028-2030, supporting a potential 20% price increase from current levels. The analyst sees a safe entry point today with a target price of around $1,950 based on 2028 earnings, factoring in currency risks within the margin assumptions.

More News

AMD turned $10,000 into $700,000 over 10 years, vastly outperforming the S&P 500's $42,000.

AMD turned $10,000 into $700,000 over 10 years, vastly outperforming the S&P 500's $42,000.

Over the past decade, an investment of $10,000 in AMD grew to more than $700,000, significantly outperforming the S&P 500, which turned the same amount into about $42,000. This highlights AMD's exceptional growth and strong market performance compare...

Market News
Bullish
51 minutes ago
TTM Technologies Q2 revenue nearly doubles, stock upgraded to Buy with $219 target.

TTM Technologies Q2 revenue nearly doubles, stock upgraded to Buy with $219 target.

TTM Technologies reported strong Q2 results, driven by nearly doubling revenue in data center and networking segments year-over-year. The company's backlog reached $1.7 billion, supporting continued sales growth, especially fueled by AI-related deman...

Analyst Insights
Bullish
4 hours ago
Zoetis cuts guidance after mixed Q2 results, but long-term outlook remains positive.

Zoetis cuts guidance after mixed Q2 results, but long-term outlook remains positive.

Zoetis reported mixed earnings for Q2 and lowered its future guidance, reflecting challenges in U.S. pet-related sales. However, strong performance in other business segments helps balance the impact. Despite near-term difficulties, the overall risk/...

Company Fundamentals
Neutral
4 hours ago
Early trial shows strong pancreatic cancer response for vopimetostat combo, but more data needed.

Early trial shows strong pancreatic cancer response for vopimetostat combo, but more data needed.

Tango Therapeutics' drug vopimetostat combined with daraxonrasib has shown a promising early signal in treating pancreatic cancer, based on a small group of 12 previously treated patients. A larger Phase 3 trial is planned to test the drug as a first...

Market News
Bullish
4 hours ago
Church & Dwight rated Buy on strong organic growth and margin expansion potential

Church & Dwight rated Buy on strong organic growth and margin expansion potential

Church & Dwight is rated Buy due to strong volume-driven organic growth, market share gains, and consistent outperformance of guidance. The company’s strategy to acquire and grow underpenetrated, high-margin brands like TheraBreath and Hero supports ...

Analyst Insights
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App